Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
New analyses from the head-to-head FLAME study confirmed that Ultibro® Breezhaler® is a more effective option for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide®, across different patient sub-groups[1-10]. These findings are being presented at the 2016 European Respiratory Society (ERS) International Congress this week in London, UK.In the new analyses, once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of all exacerbations (mild, moderate and severe), regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels (a type of white blood cells) and previous inhaled corticosteroid (ICS) use[4,5], versus twice-daily Seretide 50/500 mcg. Specifically, among patients with the severest forms of COPD**, Ultibro Breezhaler significantly reduced the rate of exacerbations and improved their health status versus the commonly used ICS/LABA*** combination. In addition, patients using Ultibro Breezhaler needed less rescue medication during the day.
BARCELONA, Spain, Sept. 5, 2016 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with more than 75-year legacy of improving people's health and well-being, today celebrated the opening of its new training center in Dubai. Created to support the company's growing Diagnostic business, the center will offer single and multi-day training courses for laboratory technicians, engineers, and specialists working with the company's broad portfolio of Transfusion Medicine and Clinical Diagnostic instruments, assays, and software. The center will also train attendees on associated best practices in the laboratory.
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven® (eribulin) in the Treatment of Advanced Liposarcoma
Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcomaThe German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which suggests that on formal or methodological grounds, respectively, no additional benefit has been proven for Halaven® (eribulin) versus established comparator therapies - as defined by the Federal Joint Committee (G-BA) - for the treatment of unresectable advanced or metastatic liposarcomas. The dossier submitted by Eisai for the assessment included a direct comparison to dacarbazine (based on Eisai's phase III study 309) as well as an indirect comparison to trabectedin. With its suggestion, IQWiG ignores pivotal phase III data which demonstrated clearly that eribulin is the first and only single agent therapy to show a statistically significant overall survival advantage in advanced liposarcoma."Eribulin has demonstrated a statistically significant survival advantage over dacarbazine in the treatment of advanced liposarcoma. This is a very rare and difficult to treat type of soft tissue sarcoma for which treatment options are few and existing therapies are associated with only limited efficacy. The clinical importance of this unprecedented survival benefit cannot be overstated for people who live with advanced liposarcoma and urgently need new and effective treatment options, such as eribulin," comments Dr. Helga Schmitz, Medical Director, Eisai GmbH.
Novel Antibacterial Drug, exeporfinium chloride, Delivers Encouraging Safety, Tolerability and Efficacy Data in US Clinical Trial
PRNewswire/ --In Development for Prevention of Post-Surgical Staphylococcal InfectionsDestiny Pharma Ltd, a leading clinical stage biopharmaceutical company focused on developing antibacterial medicines, today announced the results of a US clinical trial of the novel preventive anti-bacterial drug exeporfinium chloride (XF-73). The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, and was conducted at the NIAID Clinical Trials Unit at Case Western Reserve University in Cleveland and at Anaheim Clinical Trials in California.
Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society (ERS) International Congress on Sunday 4th September in London, (abstract number OA249).
A new study shows the benefits of endobronchial valve Pulmonx Zephyr in patients with homogeneous emphysema of Results published in the American Journal of Respiratory and Critical Care Medicine showed significant improvements in lung function, exercise tolerance and quality of life for patients
REDWOOD CITY, CA - ( BUSINESS WIRE ) - The positive results of the IMPACT study shows that patients with homogeneous emphysema benefit from treatment with valves endobronchial Zephyr® (VEB) exclusive s Pulmonx Corporation, according a new study published online in the journal American Journal of Respiratory and Critical Care Medicine . Preselected patients using the Chartis® system and treated with VEB experienced clinically significant improvements in lung function, exercise tolerance and quality of life compared to the control group. These data indicate that EBV therapy can benefit many more patients than we thought before. To learn more, visit www.pulmonx.com